All enrolled individuals who obtained no less than just one dose of zosuquidar or placebo during induction were monitored with the incidence of adverse events (439 patients, 219 on zosuquidar and 210 on placebo). The commonest adverse gatherings have been related to the period of extended and sizeable myelosuppression as https://gregorynuzgk.blogscribble.com/28098436/glibornuride-can-be-fun-for-anyone